EM1802F “Managing the Cardiovascular Risk in Cancer Therapy: A Paradigm Shift?” (IM GR-020218)

The purpose of this presentation is to describe recent advancements at the interface of cardiology and oncology that support the cardiovascular health of cancer patients who receive treatments with potentially cardiotoxic effects.

Cardio-oncology / onco-cardiology is a new interface subspecialty that bridges cardiology and hematology-oncology to support the cardiovascular health of patients with hematologic and oncologic malignancies. Tremendous progress in the early diagnosis and treatment of cancer has resulted in the last 5 decades in a significant increase in cancer survival. Life with and after cancer is a reality for many more patients, so that by 2026 there will be more than 20 million cancer survivors nationwide. The ages of these survivors will span a wide spectrum, as more than 80% of children treated for malignancies survive more than 5 years. Unfortunately some of the therapies effective to treat malignancies have long term cardiovascular toxicity, decreasing life expectancy after surviving cancer. Therefore, significant efforts have been made to develop a focused approach to the diagnosis and management of cardiovascular complications of cancer treatment. Recognizing the vulnerable population and the potential cardiotoxic therapeutic classes, and implementing guideline based approaches, including referral to a cardio-oncology clinic, can help to improve cardiovascular outcomes in this patient population.

Download Protocol

Target Audience

UT Southwestern faculty, fellows, residents and medical students, community physicians, nurse clinicians, physician assistants and nurses.

Learning Objectives

At the conclusion of this activity, the participant should be able to:

  • Recognize characteristics of the patients vulnerable from cardiovascular perspective
  • Recognize the major categories of cardiotoxic oncotherapies
  • Integrate clinically current guideline recommendations for screening and management of cardiovascular complications
  • Recognize the rapid progression of molecular targets in cancer and their potential cardiovascular side effects
  • Appreciate future research direction in early diagnosis of cardiotoxicity
Course summary
Available credit: 
  • 1.00 AMA
Course opens: 
02/07/2018
Course expires: 
03/09/2018
Cost:
$0.00
Rating: 
0

Vlad G. Zaha, M.D., Ph.D. 
Assistant Professor of Internal Medicine 
Division of Cardiology

Dr. Zaha is leading the Cardio-Oncology Clinic within the Clinical Heart Center, provides multimodality cardiovascular imaging diagnosis, including Echocardiography, Nuclear Cardiology and Cardiac MRI, and acts as a Liaison for the Center for Translational Medicine at the Advanced Imaging Research Center at UT Southwestern Medical Center. His research and clinical interests involve non-invasive cardiac mechanical and metabolic phenotyping for early diagnosis and guidance in the management of cardiomyopathies using multi-modality cardiac imaging modalities such as echocardiographic strain imaging, radioactive PET tracers, and multi-parametric cardiac MRI, as well as the development of novel non-radioactive hyperpolarized carbon-13 MRI spectroscopic imaging methodology for translational cardiac investigations. 

Available Credit

  • 1.00 AMA

Accreditation Period

Course opens: 
02/07/2018
Course expires: 
03/09/2018

Price

Cost:
$0.00
Please login or create an account to take this course.

Required Hardware/software

Activities should be run with recent versions of common browsers, including Internet Explorer, Firefox and Google Chrome